Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eyes Turn to SGLT2 Inhibitors after Entresto’s Narrow Miss in HFpEF
October 16, 2019
- AZ, Sanofi Kick Off Japan PIII for RSV Prevention
October 15, 2019
- MSD Seeking to Trim 250 Jobs in Japan
October 15, 2019
- Japan Ethical Drug Market Forecast at 8.9 Trillion Yen in 2026: Fuji Keizai
October 15, 2019
- Shionogi Signs New Mycobacterial Deal with Hsiri
October 15, 2019
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- All Eyes on Performance of Top-2 Anti-Flu Drugs Xofluza, Inavir as Flu Seasons Approaches
October 11, 2019
- Daiichi Sankyo’s AML Drug Vanflyta Now Available
October 11, 2019
- AZ, Keio Univ. Pair Up to Create Real World Evidence in Healthcare
October 11, 2019
- GSK Japan Ups Recall Level for Zantac to “Class I”
October 10, 2019
- Sosei Bags US$3 Million from Genentech on Nomination of New GPCR Disease Target
October 10, 2019
- Mitsubishi Tanabe Gains Japan, Asian Rights for Viela Bio's Inebilizumab
October 10, 2019
- Meiji to Strengthen Contract Manufacturing, Aims to Produce 3 Billion Tablets Annually for Japan Market
October 10, 2019
- Bayer, RIKEN Innovation Tie Up on Drug Discovery
October 9, 2019
- AbbVie Japan Set to Join Oncology Fray with CLL Drug, Accelerating FIH Trial Entry
October 9, 2019
- Toray Launches Recall of Careload for Possible Placebo Mix-Up
October 9, 2019
- Gilead Files JAK Inhibitor Filgotinib in Japan
October 9, 2019
- Yakult to Promote Servier’s Anticancer Agent Liposomal Irinotecan in Japan
October 9, 2019
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- Sanofi to Shed 200 Jobs in Japan
October 8, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…